Claret Medical has raised $11.2 million in a new round of equity financing, according to an SEC filing posted this week.
Money in the round came from 34 unnamed investors, according to the SEC filing, with the 1st sale dated on June 22.
Claret Medical is still looking to raise an additional $6.5 million in the round, according to the SEC filing. The company has not yet stated how it intends to use funds raised in the round.
The Santa Rosa, Calif.-based company produces the Sentinel embolic protection device designed to trap blood clots and prevent stroke during heart valve replacement procedures.
The Sentinel device uses a pair of filters, with 1 in the brachiocephalic artery and another in the left common carotid artery to trap debris released during transcatheter aortic valve replacements which could cause a cerebral embolism.
The device won de novo FDA approval early last month, and MassDevice.com spoke to CEO Azin Parhizgar about the approval and what it means for the future of Claret.
